It's interesting when one expert rates an ASX share as a buy. But, it's very intriguing when multiple analysts have a buy rating on that business.
A lot has happened in the last few weeks as a result of the Middle East events, one of which is ASX share market valuations taking a hit.
When share prices fall, it's a good idea to look for opportunities that could deliver market-beating returns over the long-term. With that in mind, let's look at two of the most well-liked ASX shares by analysts.
Image source: Getty Images
Life360 Inc (ASX: 360)
Life360 describes itself as a family connection and safety company, keeping people close to people, pets and things they care about most, with a range of services, including location sharing, safe driver reports, and crash detection with emergency dispatch.
Impressively, the business serves approximately 95.8 million monthly active users (MAU) across more than 180 countries.
According to CMC Invest, there are currently seven buy ratings on the ASX share, with an average price target of $32.80. That implies a possible rise of around 70% over the next year.
The company is growing at a very pleasing pace – compounding is a powerful financial force.
Life360 reported that in the fourth quarter of 2025, revenue increased 26% year-over-year to $146 million, while annualised monthly revenue (AMR) rose 30% to $478 million.
Those excellent levels of growth were partly driven by the fact that total MAU grew 20% year-over-year, with global paying circles increasing 26% to 2.8 million.
The paying circle growth is being driven by both the US (with 23% growth to 2 million) and internationally (with 32% growth to 0.8 million).
The company is also increasing prices, which is helping drive the average revenue per paying circle (ARPPC) – this increased by 6% year-over-year to $139.54.
Most importantly, the revenue growth is turning into rising profit, which is the key driver of increasing the intrinsic value of a business. In the 2025 fourth quarter, adjusted operating profit (EBITDA) grew 53% to $32.4 million.
Sigma Healthcare Ltd (ASX: SIG)
The company has multiple brands – Chemist Warehouse, Amcal and Discount Drug Stores. It supports Australia's largest retail network of franchised pharmacies, with more than 880 franchised pharmacies.
According to CMC Invest, there are currently six buy ratings on the business. The average price target on the ASX share is $3.25, suggesting a possible rise of 24% over the next year.
Going forward, Chemist Warehouse will be the key earnings driver of the business due to its scale and growth plans.
In the FY26 half-year result, the company's revenue grew by 14.9% to $5.5 billion, normalised operating profit (EBIT) grew 18.7% to $582.9 million and normalised net profit jumped 19.2% to $392 million.
Those numbers were largely driven by Australian Chemist Warehouse-branded stores, with sales growth of 17.2%.
In the first half of FY26, it reached 550 Australian Chemist Warehouse stores and 97 international Chemist Warehouse stores, this represented an increase from 537 Australian locations and 86 international locations at the end of FY25. Currently, international growth is focused in New Zealand and Ireland.
Through a combination of strong comparable store sales, ongoing store network expansion in Australia and overseas, and rising profit margins, it seems the ASX share is on track for a very compelling future.
According to the forecast on CMC Invest, the Sigma Healthcare share price is valued at 29x FY28's estimated earnings.
